Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Accumulated Expenses data on record, last reported at $30.1 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 35.43% year-over-year to $30.1 million; the TTM value through Sep 2025 reached $30.1 million, down 35.43%, while the annual FY2024 figure was $45.3 million, 16.81% down from the prior year.
  • Accumulated Expenses reached $30.1 million in Q3 2025 per ZNTL's latest filing, down from $35.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $54.4 million in Q4 2023 and bottomed at $30.1 million in Q3 2025.
  • Average Accumulated Expenses over 4 years is $41.9 million, with a median of $44.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 43.59% in 2023, then plummeted 35.43% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $45.4 million in 2022, then grew by 19.91% to $54.4 million in 2023, then decreased by 16.81% to $45.3 million in 2024, then tumbled by 33.45% to $30.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $30.1 million in Q3 2025, $35.3 million in Q2 2025, and $41.7 million in Q1 2025.